Alzheimer's disease: Emerging noncholinergic treatments

Geriatrics

Volumn 58, Issue SUPPL., 2003, Pages 3-15

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; ANTICONVULSIVE AGENT; ANTIOXIDANT; APOLIPOPROTEIN E4; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CASPASE; CHOLINESTERASE INHIBITOR; DICLOFENAC; DONEPEZIL; ESTROGEN; GALANTAMINE; GINKGO BILOBA EXTRACT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LITHIUM; MEMANTINE; METRIFONATE; MISOPROSTOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; RIVASTIGMINE; ROFECOXIB; SEROTONIN UPTAKE INHIBITOR; TACRINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID;

AGED; AGITATION; ALZHEIMER DISEASE; ASTHENIA; BEHAVIOR; CAREGIVER; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; COST OF ILLNESS; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; LONG TERM CARE; NEUROANATOMY; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; PREVALENCE; QUALITY OF LIFE; REVIEW; SEDATION; SENILE PLAQUE; SIDE EFFECT; UNITED STATES; VERTIGO;

EID: 0037316593     PISSN: 0016867X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Mayeux R, Sano M. Treatment of Alzheimer's disease. N Engl J Med. 1999;341:1670-1679.
2. Alzheimer's Association Web site: http://www.alz.org/AboutAD/Statistics.htm.
3. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998;88:1337-1342.
4. Small GW, McDonnell DD, Brooks RL, et al. The impact of symptom severity on the cost of Alzheimer's disease. J Am Geriatr Soc. 2002;50:321-327.
5. Small GW, Rabins PV, Barry PB, et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA. 1997;278:1363-1371.
6. Arnaiz E, Jelic V, Almkvist O, et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport. 2001;12:851-855.
7. Selkoe DJ. Alzheimer's disease: genotypes, phenotypes, and treatments. Science. 1997;275:630-631.
8. Cagnin A, Brooks DJ, Kennedy AM, et al. In-vivo measurement of activated microglia in dementia. Lancet. 2001;358:461-467.
9. Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1154-1166.
10. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease, Donepezil Study Group. Neurology. 1998;50:136-145.
11. Doody RS, Geldmacher DS, Gordon B, et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol. 2001;58:427-433.
12. Farlow M, Anand R, Messina J et al. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol. 2000;44:236-241.
13. Corey-Bloom J, Anand R, Veach J, for the ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Psychopharmacol, 1998;1:55-65.
14. Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology. 2000;54:2261-2268.
15. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001;57:489-495.
16. Doody RS Kershaw P. The cognitive benefits of Galantamine are sustained for at least 24 months: results of a long-term extension in Alzheimer's disease. Neurology. 2001;56(suppl 3):A456.
17. Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology. 2001;57:481-488.
18. Winblad B. Maintaining functional and behavioral abilities in Alzheimer disease. Alzheimer Dis Assoc Disord. 2001;15(suppl 1):S34-S40.
19. Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology. 2001;57:613-620.
20. Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology. 2000;54:2269-2276.
21. Cummings JL, Anand R, Koumaras B, Hartman R. Behavioral benefits in Alzheimer's disease patients residing in a nursing home following 52 weeks of treatment with rivastigmine. Poster presented at: American Psychiatric Association 2000 Annual Meeting; May 13-18, 2000;Chicago, Ill.
22. Doraiswamy PM, Krishnan KR, Anand R, et al. Long-term effects of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits? Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:705-712.
23. Le Bars PL, Katz MM, Berman N, et al. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA. 1997;278:1327-1332.
24. Wettstein A. Cholinesterase inhibitors and Ginkgo extracts-are they comparable in the treatment of dementia? Comparison of published placebo-controlled efficacy studies of at least six months' duration. Phytomedicine. 2000;6:393-401.
25. van Dongen MCJM, Van Rossum E, Knipschild PG. Efficacy of Ginkgo biloba extracts: evidence from randomized clinical trials. In: Van Beck TA, ed. Ginkgo Biloba. Amsterdam: Harwood Academic Publishers, 2000.
26. van Dongen MC, van Rossum E, Kessels AG, et al. The efficacy of ginkgo for elderly people with dementia and age-associated memory impairment: new results of a randomized clinical trial. J Am Geriatr Soc. 2000;48:1183-1194.
27. Doraiswamy PM, Bieber F, Kaiser L, et al. The Alzheimer's Disease Assessment Scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials. Neurology. 1997;48:1511-1517.
28. Scharf S, Mander A, Ugoni A, et al. A double-blind placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology. 1999;53:197-201.
29. Eighth International Conference on Alzheimer's Disease and Related Disorders. Stockholm, Sweden; July 20-25, 2002.
30. Parsons CG, Danysz W, Quack G. Memantine and the amino-alkyl-cyclohexane MRZ 2/579 are moderate affinity uncompetitive NMDA receptor antagonistsin vitro characterisation. Amino Acids. 2000;19:157-166.
31. Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist-a review of preclinical data. Neuropharmacology. 1999;38:735-767.
32. Ruther E, Glaser A, Bleich S, et al. A prospective PMS study to validate the sensitivity for change of the D-scale in advanced stages of dementia using the NMDA-antagonist memantine. Pharmacopsychiatry 2000;33:103-108.
33. Winblad B, Poritis N. Memantine in severe dementia results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry. 1999;14:135-146.
34. Reisberg B, Ferris S. Long-term treatment with the NMDA antagonist memantine: results of a 24-week open-label extension study in moderate to severe Alzheimer's disease (abstract). Neurobiol Aging. 2002;23(Supp: 1):S555. (International Conference on Alzheimer's Disease; July 2002).
35. Lyketsos CG, Steinberg M, Tschanz JT, et al. Mental and behavioral disturbances in dementia: findings from the Cache County study on Memory in Aging. Am J Psychiatry. 2000;157:708-714.
36. Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry. 1999;60:107-115.
37. De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999;53:946-955.
38. Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry. 2000;57:968-976.
39. Tariot PN, Erb R, Podgorski CA, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry. 1998;155:54-61.
40. Olin JT, Fox LS, Pawluczyk S, et al. A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease. Am J Geriatr Psychiatr. 2001;9:400-405.
41. Porsteinsson AP, Tariot PN, Erb R, et al. Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatric Psychiatry. 2001;9:58-66.
42. Tariot PN, Schneider LS, Mintzer JE, et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double-blind, placebo-controlled trial. Curr Ther Res Clin Exp. 2001;62:51-67.
43. Pollock BG, Mulsant BH, Rosen J, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized demented patients. Am J Psychiatry. 2002;159:460-465.
44. in t'Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer's disease. N Engl J Med. 2001;345:1515-1521
45. Zandi PP, Anthony JC, Hayden KM, et al. Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology. 2002;59:880-886.
46. Lindsay J, Laudn D, Verreault R, et al Risk factors for Alzheimer's disease. prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol. 2002;156:445-453.
47. Breitner JC, Zandi PP. Do nonsteroidal anti-inflammatory drugs reduce the risk of Alzheimer's disease? N Engl J Med. 2001;345:1567-1568.
48. Martin BK, Meinert CL, Breitner, JC. Double placebo design in a prevention trial for Alzheimer's disease. Control Clin Trials. 2002;23:93-99.
49. Weggen S. Eriksen JL, Das P, et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature. 2001;414:212-216.
50. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alphatocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med. 1992;336:1216-1222.
51. MRC/BHF Heart Protection Study of high-risk Individuals: a randomized placebo-controlled trial. Lancet. 2002;360:23-33.
52. Grundman, et al. Use of brain MRI volumetric analysis in a mild cognitive impairment trial to delay the diagnosis of Alzheimer's disease 2000. New York, NY Springer Publishing Co, 2002.
53. Jick H, Zomberg LG, Jick SS, et al. Stastins and the risk of dementia. Lancet 2000;356:1627-1631.